tiprankstipranks
NervGen Pharma (NGEN)
NASDAQ:NGEN
US Market
NGEN
NervGen Pharma
RESEARCH TOOLSreports
Want to see NGEN full AI Analyst Report?

NervGen Pharma (NGEN) Ratios

93 Followers

NervGen Pharma Ratios

NGEN's free cash flow for Q4 2025 was C$0.00. For the 2025 fiscal year, NGEN's free cash flow was decreased by C$ and operating cash flow was C$0.00. See a summary of the company’s cash flow.
Ratios
TTM
Mar 26Mar 25Mar 24Dec 22
Liquidity Ratios
Current Ratio
 ― 1.16 1.12 0.83 2.27
Quick Ratio
 ― 1.16 1.12 0.83 2.27
Cash Ratio
 ― 1.12 1.02 0.77 2.20
Solvency Ratio
 ― -2.23 -1.41 -1.46 -1.73
Operating Cash Flow Ratio
 ― -0.99 -1.00 -0.75 -1.74
Short-Term Operating Cash Flow Coverage
 ― 0.00 -173.20 0.00 0.00
Net Current Asset Value
C$ ―C$ 3.07MC$ 1.46MC$ -2.73MC$ 12.73M
Leverage Ratios
Debt-to-Assets Ratio
 ― <0.01 <0.01 0.01 0.01
Debt-to-Equity Ratio
 ― <0.01 0.04 -0.10 0.02
Debt-to-Capital Ratio
 ― <0.01 0.04 -0.11 0.02
Long-Term Debt-to-Capital Ratio
 ― 0.00 0.00 0.00 0.00
Financial Leverage Ratio
 ― 6.68 7.56 -6.59 1.77
Debt Service Coverage Ratio
 ― 0.00 -246.03 0.00 -33.96
Interest Coverage Ratio
 ― 0.00 0.00 0.00 -44.35
Debt to Market Cap
 ― 0.00 <0.01 0.00 0.00
Interest Debt Per Share
 ― <0.01 <0.01 <0.01 0.02
Net Debt to EBITDA
 ― 3.90 0.72 0.65 1.10
Profitability Margins
Gross Profit Margin
―0.00%0.00%0.00%0.00%
EBIT Margin
―0.00%0.00%0.00%0.00%
EBITDA Margin
―0.00%0.00%0.00%0.00%
Operating Profit Margin
―0.00%0.00%0.00%0.00%
Pretax Profit Margin
―0.00%0.00%0.00%0.00%
Net Profit Margin
―0.00%0.00%0.00%0.00%
Continuous Operations Profit Margin
―0.00%0.00%0.00%0.00%
Net Income Per EBT
―100.00%100.00%100.00%87.38%
EBT Per EBIT
―175.91%96.29%125.91%90.79%
Return on Assets (ROA)
―-190.08%-123.19%-169.10%-75.84%
Return on Equity (ROE)
―-1268.86%-931.69%1114.03%-134.51%
Return on Capital Employed (ROCE)
―-721.31%-964.50%933.90%-167.10%
Return on Invested Capital (ROIC)
―-719.57%-929.53%981.10%-145.09%
Return on Tangible Assets
―-193.49%-126.21%-176.03%-77.23%
Earnings Yield
―-10.89%-5.80%-13.98%-21.49%
Efficiency Ratios
Receivables Turnover
 ― 0.00 0.00 0.00 0.00
Payables Turnover
 ― 0.00 0.00 0.26 0.06
Inventory Turnover
 ― 0.00 0.00 0.00 0.00
Fixed Asset Turnover
 ― 0.00 0.00 0.00 0.00
Asset Turnover
 ― 0.00 0.00 0.00 0.00
Working Capital Turnover Ratio
 ― 0.00 0.00 0.00 0.00
Cash Conversion Cycle
 ― 0.00 0.00 -1.39K -6.35K
Days of Sales Outstanding
 ― 0.00 0.00 0.00 0.00
Days of Inventory Outstanding
 ― 0.00 0.00 0.00 0.00
Days of Payables Outstanding
 ― 0.00 0.00 1.39K 6.35K
Operating Cycle
 ― 0.00 0.00 0.00 0.00
Cash Flow Ratios
Operating Cash Flow Per Share
 ― -0.27 -0.17 -0.19 -0.34
Free Cash Flow Per Share
 ― -0.27 -0.17 -0.19 -0.34
CapEx Per Share
 ― 0.00 0.00 <0.01 <0.01
Free Cash Flow to Operating Cash Flow
 ― 1.00 1.00 1.01 1.00
Dividend Paid and CapEx Coverage Ratio
 ― 0.00 0.00 -79.88 -842.65
Capital Expenditure Coverage Ratio
 ― 0.00 0.00 -79.88 -842.65
Operating Cash Flow Coverage Ratio
 ― -2.33K -159.48 -57.28 -62.74
Operating Cash Flow to Sales Ratio
 ― 0.00 0.00 0.00 0.00
Free Cash Flow Yield
―-4.81%-4.07%-7.14%-21.14%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 ― -9.18 -17.23 -7.15 -4.65
Price-to-Sales (P/S) Ratio
 ― 0.00 0.00 0.00 0.00
Price-to-Book (P/B) Ratio
 ― 116.50 160.55 -79.68 6.26
Price-to-Free Cash Flow (P/FCF) Ratio
 ― -20.77 -24.56 -14.00 -4.73
Price-to-Operating Cash Flow Ratio
 ― -20.77 -24.56 -14.17 -4.74
Price-to-Earnings Growth (PEG) Ratio
 ― -0.06 1.61 -0.61 -0.74
Price-to-Fair Value
 ― 116.50 160.55 -79.68 6.26
Enterprise Value Multiple
 ― -67.76 -16.58 -8.43 -3.09
Enterprise Value
 ― 382.99M 275.54M 148.62M 62.07M
EV to EBITDA
 ― -67.76 -16.58 -8.43 -3.09
EV to Sales
 ― 0.00 0.00 0.00 0.00
EV to Free Cash Flow
 ― -19.64 -23.54 -12.99 -3.49
EV to Operating Cash Flow
 ― -19.64 -23.54 -13.16 -3.49
Tangible Book Value Per Share
 ― 0.04 0.02 -0.04 0.25
Shareholders’ Equity Per Share
 ― 0.05 0.03 -0.03 0.26
Tax and Other Ratios
Effective Tax Rate
 ― 0.00 0.00 0.00 0.13
Revenue Per Share
 ― 0.00 0.00 0.00 0.00
Net Income Per Share
 ― -0.61 -0.25 -0.38 -0.34
Tax Burden
 ― 1.00 1.00 1.00 0.87
Interest Burden
 ― 7.73 1.00 1.26 0.90
Research & Development to Revenue
 ― 0.00 0.00 0.00 0.00
SG&A to Revenue
 ― 0.00 0.00 0.00 0.00
Stock-Based Compensation to Revenue
 ― 0.00 0.00 0.00 0.00
Income Quality
 ― 0.44 0.70 0.50 0.86
Currency in CAD